MUK Nine b: OPTIMUM Treatment Protocol
Condition(s):Multiple MyelomaLast Updated:May 25, 2022Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:May 25, 2022Active, not recruiting
Condition(s):Acute Myeloid Leukemia; Myelodysplastic Syndromes; Transplant-Related Hematologic MalignancyLast Updated:November 18, 2023Completed
Condition(s):Melanoma (Skin)Last Updated:March 15, 2012Completed
Condition(s):Brain and Central Nervous System TumorsLast Updated:April 8, 2013Completed
Condition(s):Melanoma (Skin)Last Updated:June 19, 2013Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:August 3, 2022Recruiting
Condition(s):Diffuse Large B-Cell Lymphoma; IPI≥2Last Updated:February 15, 2011Unknown status
Condition(s):Leukemia; Chronic Myelogenous LeukemiaLast Updated:February 3, 2016Completed
Condition(s):Lymphoma, Diffuse Large-Cell B-cell; Diffuse, Large B-cell Lymphoma; Lymphoma, Diffuse Large-Cell; Large-Cell Lymphoma, DiffuseLast Updated:December 17, 2019Withdrawn
Condition(s):Fatigue; Febrile Neutropenia; Solid NeoplasmLast Updated:October 22, 2018Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.